+

WO2002003792A3 - Transgenic mice containing targeted protease inhibitor gene disruptions - Google Patents

Transgenic mice containing targeted protease inhibitor gene disruptions Download PDF

Info

Publication number
WO2002003792A3
WO2002003792A3 PCT/US2001/021824 US0121824W WO0203792A3 WO 2002003792 A3 WO2002003792 A3 WO 2002003792A3 US 0121824 W US0121824 W US 0121824W WO 0203792 A3 WO0203792 A3 WO 0203792A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease inhibitor
transgenic mice
inhibitor gene
mice containing
gene disruptions
Prior art date
Application number
PCT/US2001/021824
Other languages
French (fr)
Other versions
WO2002003792A2 (en
Inventor
Keith D Allen
Original Assignee
Deltagen Inc
Keith D Allen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deltagen Inc, Keith D Allen filed Critical Deltagen Inc
Priority to AU2001273352A priority Critical patent/AU2001273352A1/en
Publication of WO2002003792A2 publication Critical patent/WO2002003792A2/en
Publication of WO2002003792A3 publication Critical patent/WO2002003792A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a target protease inhibitor gene, more specifically a systatin or a stefin, a serine protease inhibitor or WDNM1. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
PCT/US2001/021824 2000-07-11 2001-07-10 Transgenic mice containing targeted protease inhibitor gene disruptions WO2002003792A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001273352A AU2001273352A1 (en) 2000-07-11 2001-07-10 Transgenic mice containing targeted protease inhibitor gene disruptions

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US21732700P 2000-07-11 2000-07-11
US21732900P 2000-07-11 2000-07-11
US21778300P 2000-07-11 2000-07-11
US21762500P 2000-07-11 2000-07-11
US60/217,329 2000-07-11
US60/217,327 2000-07-11
US60/217,625 2000-07-11
US60/217,783 2000-07-11
US21801700P 2000-07-12 2000-07-12
US60/218,017 2000-07-12
US24941000P 2000-11-15 2000-11-15
US60/249,410 2000-11-15
US26212601P 2001-01-16 2001-01-16
US60/262,126 2001-01-16
US30089601P 2001-06-26 2001-06-26
US60/300,896 2001-06-26

Publications (2)

Publication Number Publication Date
WO2002003792A2 WO2002003792A2 (en) 2002-01-17
WO2002003792A3 true WO2002003792A3 (en) 2003-04-10

Family

ID=27575198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021824 WO2002003792A2 (en) 2000-07-11 2001-07-10 Transgenic mice containing targeted protease inhibitor gene disruptions

Country Status (2)

Country Link
AU (1) AU2001273352A1 (en)
WO (1) WO2002003792A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014797A2 (en) * 1995-10-20 1997-04-24 Dana-Farber Cancer Institute Cystatin m, a novel cysteine proteinase inhibitor
WO1998054307A1 (en) * 1997-05-30 1998-12-03 Schering Aktiengesellschaft Knockout mice and their progeny with disrupted serine protease genes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014797A2 (en) * 1995-10-20 1997-04-24 Dana-Farber Cancer Institute Cystatin m, a novel cysteine proteinase inhibitor
WO1998054307A1 (en) * 1997-05-30 1998-12-03 Schering Aktiengesellschaft Knockout mice and their progeny with disrupted serine protease genes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 28 May 1998 (1998-05-28), TSUI FWL ET AL.: "Mouse cysteine proteinase inhibitor (MS2) mRNA sequence", XP002212903, retrieved from E.B.I., HINXTON, U.K. Database accession no. M92418 *
PENNACCHIO L A ET AL: "Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice.", NATURE GENETICS. UNITED STATES NOV 1998, vol. 20, no. 3, November 1998 (1998-11-01), pages 251 - 258, XP002212682, ISSN: 1061-4036 *
TSUI FLORENCE W L ET AL.:: "Molecular characterization and mapping of murine genes encoding three members of the stefin family of cysteine proteinase inhibitors.", GENOMICS, vol. 15, no. 3, 1993, pages 507 - 514, XP001104072 *

Also Published As

Publication number Publication date
AU2001273352A1 (en) 2002-01-21
WO2002003792A2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
WO2002079440A8 (en) Transgenic mice containing gpcr5-1 gene disruptions
WO2002046390A3 (en) Transgenic mice containing rptpb tyrosine phosphatase gene disruptions
WO2002079424A3 (en) TRANSGENIC MICE CONTAINING β3GALT2 GENE DISRUPTIONS
WO2002079438A3 (en) Ogri gene disruptions, compositions and methods relating thereto
WO2002079444A3 (en) Transgenic mice containing msk2 serine/threonine kinase gene disruptions
WO2003026395A3 (en) Mo54 gene disruptions, compositions and methods related thereto
WO2001067855A3 (en) Transgenic mice containing targeted gene disruptions
WO2002045498A3 (en) Transgenic mice containing channel protein target gene disruptions
WO2002040662A3 (en) Transgenic mice containing targeted gene disruptions
WO2002003789A3 (en) Transgenic mice containing targeted gpcr gene disruptions
WO2002081658A8 (en) Transgenic mice containing cacnb4 calcium ion channel gene disruptions
WO2002001950A3 (en) Transgenic mice containing targeted gene disruptions
WO2002003792A3 (en) Transgenic mice containing targeted protease inhibitor gene disruptions
WO2002079426A3 (en) Transgenic mice containing pai3 serine protease inhibitor gene disruptions
WO2002003788A3 (en) Transgenic mice containing targeted phosphatase gene disruptions
WO2002079414A8 (en) Transgenic mice containing clcn7 chloride channel gene disruptions
WO2002079412A3 (en) Transgenic mice containing usp3-like deubiquitinating enzyme gene disruptions
WO2002003787A3 (en) Transgenic mice containing targeted gene disruptions
WO2002003793A3 (en) Transgenic mice containing targeted gene disruptions
WO2002045491A3 (en) Transgenic mice containing protease target gene disruptions
WO2002003791A3 (en) Transgenic mice containing targeted gene disruptions
WO2003026403A3 (en) Ctsz disruptions, compositions and methods relating thereto
WO2002079420A3 (en) Adam-like protease disruptions, compositions and methods related thereto
WO2002055687A3 (en) Transgenic mice containing target gene disruptions
WO2002045500A3 (en) Transgenic mice containing ptp36 tyrosine phosphatase disruptions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载